Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
13 8월 2024 - 10:07PM
Aclarion, Inc.,
(“Aclarion” or the “Company”) (Nasdaq:
ACON, ACONW), a healthcare technology company that is
leveraging biomarkers and proprietary augmented intelligence
algorithms to help physicians identify the location of chronic low
back pain, announced today their third payer coverage of Nociscan
by Vitality in London, UK in conjunction with The London Clinic,
one of the UK’s largest and most renowned independent hospitals.
With the addition of coverage by Vitality, payer coverage for
Nociscan is now available from three major private medical
insurance groups in the UK, a global healthcare market with more
than nine million residents.
“With three of the top four private payer systems in greater
London covering Nociscan, we expect to see further coverage and
strong product adoption in the UK market,” said Brent Ness, CEO of
Aclarion. “These coverage decisions support the movement of
Nociscan into the standard of care and further validate our
strategy of partnering with strong clinical leaders in each market
to let them see the value of our technology for improving surgical
decisioning and then supporting these clinical leaders as they take
Nociscan to the payers for coverage. The London Clinic team saw the
value in Nociscan after only 20 patients and have thus far
delivered payer coverage from 3 of the top 4 private health
insurance payers in the market. We expect to replicate The London
Clinic success in driving payer coverage at each of our 10 KOL
sites in the U.S. and elsewhere around the world.”
In the UK, self-pay and private medical insurance are estimated
to represent nearly 70% of private hospital revenues with private
medical insurance becoming increasingly popular. Vitality is one of
the four leading private medical insurers in the UK with an
estimated 13% of the private medical insurance market and an
estimated one million insured customers. By joining AXA and Aviva
in covering Nociscan, almost 60% of the patients with private
insurance now have access to Nociscan.
John Lorbiecki, Aclarion CFO, added, “These significant payer
coverage decisions represent a sea change in our business. Every
medical technology or services company faces the same dilemma of
bringing new products to market. Without insurance companies paying
for a technology or service, the revenue challenge is obvious. As
soon as insurance companies recognize new innovations with an
assigned payment, the economics change considerably. We now have a
clear path to commercialization in the UK and will be allocating
resources accordingly.”
Low back pain is estimated to affect up to one third of the UK
adult population each year. The London Spine Clinic is the first
private specialist spinal unit in England and their expert spine
physicians have adopted Nociscan as an important decision support
tool to be used when diagnosing and treating chronic low back pain.
Nociscan is the first evidence-supported SaaS platform to
noninvasively help physicians distinguish between painful and
nonpainful discs in the lumbar spine by quantifying chemical
biomarkers demonstrated to be associated with disc pain. This
biomarker data is entered into proprietary algorithms to highlight
if a disc may be a source of pain, and when used with other
diagnostic tools, provides critical insights into the location of a
patient’s low back pain.
For more information about The London Clinic, please visit:
www.thelondonclinic.co.uk
For more information about the London Spine Clinic, please
visit: www.londonspineclinic.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please visit
www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company's current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
"anticipates," "believes" and "expects" or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company's current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December
31, 2023, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Disclosure
The information stated above was prepared by Aclarion and
reflects solely the opinion of Aclarion. Nothing in this statement
shall be construed to imply any support or endorsement of Aclarion
or any of its products by The London Clinic.
Investor Contacts:Kirin M. SmithPCG Advisory,
Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024